Incyte Corporation finds itself at a curious crossroads. Despite announcing encouraging clinical results from its oncology pipeline, the biopharmaceutical company's stock is experiencing a pronounced ...

In response, management revised its full-year 2026 revenue guidance downward. The company now anticipates revenue in the range of $2.82 billion to $2.86 billion, a reduction from the prior forecast of ...